- Home
- NDLS vs LIXT Comparison
NDLS vs LIXT Comparison
Compare NDLS & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- LIXT
- Stock Information
- Founded
- NDLS 1995
- LIXT 2005
- Country
- NDLS United States
- LIXT United States
- Employees
- NDLS N/A
- LIXT N/A
- Industry
- NDLS Restaurants
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- LIXT Health Care
- Exchange
- NDLS Nasdaq
- LIXT Nasdaq
- Market Cap
- NDLS 29.8M
- LIXT 24.4M
- IPO Year
- NDLS 2013
- LIXT N/A
- Fundamental
- Price
- NDLS $0.60
- LIXT $4.89
- Analyst Decision
- NDLS Buy
- LIXT
- Analyst Count
- NDLS 2
- LIXT 0
- Target Price
- NDLS $3.00
- LIXT N/A
- AVG Volume (30 Days)
- NDLS 164.5K
- LIXT 184.3K
- Earning Date
- NDLS 11-05-2025
- LIXT 11-11-2025
- Dividend Yield
- NDLS N/A
- LIXT N/A
- EPS Growth
- NDLS N/A
- LIXT N/A
- EPS
- NDLS N/A
- LIXT N/A
- Revenue
- NDLS $494,752,000.00
- LIXT N/A
- Revenue This Year
- NDLS $1.19
- LIXT N/A
- Revenue Next Year
- NDLS N/A
- LIXT N/A
- P/E Ratio
- NDLS N/A
- LIXT N/A
- Revenue Growth
- NDLS N/A
- LIXT N/A
- 52 Week Low
- NDLS $0.55
- LIXT $0.64
- 52 Week High
- NDLS $1.74
- LIXT $6.26
- Technical
- Relative Strength Index (RSI)
- NDLS 39.67
- LIXT 50.85
- Support Level
- NDLS $0.61
- LIXT $4.64
- Resistance Level
- NDLS $0.69
- LIXT $5.53
- Average True Range (ATR)
- NDLS 0.04
- LIXT 0.48
- MACD
- NDLS 0.01
- LIXT -0.08
- Stochastic Oscillator
- NDLS 23.68
- LIXT 17.89
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.